# OnCo record nct05774951 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05774951/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05774951", "NCT05774951" ;
  schema:name "A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy"@en ;
  schema:alternateName "CAMBRIA-1"@en ;
  schema:description "A phase 3 trial of Camizestrant, Tamoxifen and Exemestane in advanced solid tumours, run by AstraZeneca, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05774951/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05774951> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-03-31" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/exemestane/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .